Skip to content

Advertisement

  • Study protocol
  • Open Access
  • Open Peer Review

Rationale and design of ASPIRE-ICU: a prospective cohort study on the incidence and predictors of Staphylococcus aureus and Pseudomonas aeruginosa pneumonia in the ICU

  • 1Email authorView ORCID ID profile,
  • 1,
  • 2,
  • 3,
  • 1,
  • 2,
  • 4,
  • 4,
  • 4,
  • 4,
  • 5,
  • 1, 6 and
  • 1, 7
BMC Infectious DiseasesBMC series – open, inclusive and trusted201717:643

https://doi.org/10.1186/s12879-017-2739-4

©  The Author(s). 2017

  • Received: 17 August 2017
  • Accepted: 14 September 2017
  • Published:
Open Peer Review reports

Abstract

Background

The epidemiology of ICU pneumonia caused by Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) is not fully described, but is urgently needed to support the development of effective interventions. The objective of this study is to estimate the incidence of S. aureus and P. aeruginosa ICU pneumonia and to assess its association with patient-related and contextual risk factors.

Methods

ASPIRE-ICU is a prospective, observational, multi-center cohort study nested within routine surveillance among ICU patients in Europe describing the occurrence of S. aureus and P. aeruginosa ICU pneumonia. Two thousand (2000) study cohort subjects will be enrolled (50% S. aureus colonized) in which specimens and data will be collected. Study cohort subjects will be enrolled from a larger surveillance population, in which basic surveillance data is captured. The primary outcomes are the incidence of S. aureus ICU acquired pneumonia and the incidence of P. aeruginosa ICU acquired pneumonia through ICU stay.

The analysis will include advanced survival techniques (competing risks and multistate models) for each event separately as well as for the sub-distribution of ICU pneumonia to determine independent association of outcomes with risk factors.. A risk prediction model will be developed to quantify the risk for acquiring S. aureus or P. aeruginosa ICU pneumonia during ICU stay by using a composite score of independent risk factors.

Discussion

The diagnosis of pathogen-specific ICU pneumonia is difficult, however, the criteria used in this study are objective and comparable to those in the literature.

Trial registration

This study is registered on clinicaltrials.gov under identifier NCT02413242.

Keywords

  • ICU pneumonia
  • S. aureus
  • P. aeruginosa
  • Vap

Background

Patients hospitalized in the Intensive Care Unit (ICU) are at risk of acquiring pneumonia, especially if they are mechanically ventilated. Despite extensive efforts, ICU-acquired pneumonia continues to be one of the most frequently occurring complications in the ICU and increases morbidity as well as mortality [1, 2]. Accurately describing and predicting the occurrence of ICU pneumonia is difficult as a result of inconsistencies in the case definition and surveillance methods in different countries [1, 3]. The need for an accurate and standardized prognosis is important considering current interventions are preventive rather than therapeutic [4]. As part of the COMBACTE consortium (COMBatting AntibiotiC resisTance in Europe), two monoclonal antibodies (mAbs) are currently being developed that target S. aureus and P. aeruginosa, respectively [5, 6]. Both bacteria are frequently occurring causative pathogens of ICU pneumonia and administration of a mAb may prevent the development of ICU pneumonia with these pathogens [7, 8]. Prospective studies can assess possible risk factors that can identify subsets of patients that may benefit most from these interventions. Thus, the goal of this study is to systematically assess the impact of patient-related and contextual factors on the incidence of S. aureus and P. aeruginosa ICU pneumonia in Europe and to identify the patient subgroups that are at greater risk for disease and bear a disproportionate disease burden. These objectives will directly contribute to the sample size and feasibility calculations for clinical trial design of the mAb interventions [8].

Methods

Objectives

The primary objectives of this study are to determine the incidence of:
  1. (1)

    S. aureus ICU pneumonia through ICU stay; and

     
  2. (2)

    P. aeruginosa ICU pneumonia through ICU stay; and

    their independent associations with patient-related factors (e.g. colonization status, baseline serum antibody levels against S. aureus or P. aeruginosa antigens) and contextual factors.

     

The key secondary objectives are to develop risk prediction models to quantify the risk of acquiring (i) S. aureus or (ii) P. aeruginosa ICU pneumonia during ICU stay, by using a composite score of independent risk factors identified through primary objective 1 and 2. Other secondary and exploratory objectives can be found on ClinicalTrials.gov, under identifier NCT02413242, or in the online (Additional file 1: S.01).

Study design

ASPIRE-ICU (Advanced understanding of S taphylococcus aureus and Pseudomonas aeruginosa Infections in EuRopE - Intensive Care Units) is a multi-center, prospective, observational cohort study nested within ongoing routine surveillance among ICU patients in Europe. The study is composed of two study populations, the surveillance population and study cohort population. The study cohort is nested within the larger surveillance population; this means that all data and specimens collected specifically for study cohort participants is in addition to data already captured by ways of surveillance. An overview of the schedule of procedures, including all sample collection types and time points can be found in the online (Additional file 1: Table S.02).

Study populations and recruitment

Surveillance population

Patients eligible to participate in the surveillance population must be on mechanical ventilation (MV) upon or (expected to be) within 24 h after ICU admission and have an expected length of stay (LOS) of at least 48 h. Patients with an expected ICU stay of less than 48 h are at a lower risk for developing ICU infections since this population is generally healthier, without significant comorbidities and shorter in the ICU.

The surveillance population are considered to be the source population from which the study cohort subjects are derived. No informed consent is required for participation in the surveillance population, but depending on local legislation, patients of the surveillance population will receive information (i.e. leaflet/flyer) on the ASPIRE-ICU study and are able to deny use of their de-identified data for scientific purposes.

Study cohort population

Surveillance patients that meet the eligibility criteria described below for the study cohort population will be enrolled. 2000 study cohort subjects are required to meet the objectives of this study. Study cohort subjects are approached for informed consent based on their S. aureus colonization status at ICU admission. Subjects will be enrolled in a 1:1 ratio of S. aureus colonized subjects to non S. aureus colonized subjects with 1000 subjects in each stratum. A similar temporal distribution of enrolled S. aureus colonized and non S. aureus -colonized subjects will be managed by selecting the first non-colonized subject after including a colonized subject. For subjects unable to provide consent for any reason, a legally accepted representative may consent on the subject’s behalf at the time of enrollment.

Inclusion criteria for study cohort
  1. 1.

    Participant is 18 years or older at the time of enrollment.

     
  2. 2.

    Participant is on mechanical ventilation at ICU admission, or is (expected to be) within 24 h thereafter, based on investigator’s judgment.

     
  3. 3.

    Expected stay in ICU is 48 h or longer based on investigator’s judgment.

     
  4. 4.

    S. aureus colonization status is known within 72 h after start of first episode of mechanical ventilation and according to the result, the patient qualifies for enrollment.

     
  5. 5.

    Written informed consent from subject / legally accepted representative within 72 h after start of first episode of mechanical ventilation.

     
Exclusion criteria for study cohort
  1. 1.

    Previous participation as a subject in the study cohort of this study.

     
  2. 2.

    Simultaneous participation of the subject in any preventive experimental study into anti-staphylococcus or anti-pseudomonas aeruginosa interventions.

     
  3. 3.

    Expected death (moribund status) within 48 h, or ICU discharge of the participant within 24 h, at the moment of informed consent.

     

Study outcome definitions

Considering that the definition of our primary outcome, ICU pneumonia caused by S. aureus or P. aeruginosa, is very extensive, we would like to refer to the (Additional file 1: S.03) containing the full definition. In summary, ICU pneumonia is defined as pneumonia occurring ≥48 h after admission to the ICU and is confirmed by a new or worsening infiltrate on chest X-ray or CT-thorax. Furthermore, the patient must fulfill specific clinical criteria (for example abnormal temperature, production of sputum, auscultatory abnormalities, acute changes in the ventilatory support system), in addition to at least 1 microbiological criterion (positive respiratory specimen, blood culture, pleural fluid aspirate or lung tissue culture).

Site selection

In total, 30 sites in 11 countries were selected from sources including but not limited to the COMBACTE CLIN-Net and LAB-Net databases [7]. To ensure the pan-European continent is represented, there is at least one country included from the Northern / Southern / Eastern and Western region of Europe. The selected sites adequately balance different factors such as geography, background antibiotic resistance prevalence, etc.. To ensure enrollment is met within the expected timelines, back-up sites were selected for various reasons (i.e. low enrollment numbers, decline further participation) that can supplement or replace primary sites selected. For each site also a local laboratory was selected to participate in the study.

A Site Selection Committee selected sites and laboratories based on pre-defined criteria in the Site Selection Plan. Assessment of these criteria was aided by site feasibility questionnaires. Participating ICUs must have a routine S. aureus screening protocol in order to be selected for participation.

Screening should consist of a minimum of one nasal swab and one lower respiratory tract (LRT) sample analyzed locally on the day of ICU admission. The LRT sample is defined as the collection of an endotracheal aspirate (ETA) sample, or, if an ETA cannot be collected, a sputum sample may be taken. As an exception, for routine S. aureus colonization screening at ICU admission only, if both the ETA and sputum cannot be collected, a throat swab may be taken.

Statistical analysis

Sample size calculation

Sample size calculations are based on the expected incidence precision of S. aureus ICU pneumonia and P. aeruginosa ICU pneumonia, since the primary objective of the study is to identify the patient groups most at risk for this outcome.

Assuming an incidence of S. aureus ICU pneumonia of 12.5% and 1.5% in the S. aureus colonized group and non S. aureus colonized group respectively, this would result in an overall incidence of 7% within the 2000 study cohort subjects, or 140 S. aureus ICU pneumonia endpoints [9]. The overall incidence estimate would have precision of 1.12% (95% confidence interval [CI]: 5.9%–8.12%, using normal approximation).

For P. aeruginosa ICU pneumonia, the overall incidence is estimated regardless of colonization status at ICU admission. Assuming an overall incidence of P. aeruginosa ICU pneumonia of 2.5% within the 2000 study cohort subjects, this would result in 50 P. aeruginosa ICU pneumonia endpoints. The overall incidence estimate would have precision of 0.68% (95% CI 1.82%–3.18%, using normal approximation).

Planned analysis

The primary analysis will evaluate the incidence density of S. aureus or P. aeruginosa ICU pneumonia; its calculation will depend on time from admission (for outcome ICU pneumonia) or time from ventilation (for outcome ventilator-associated pneumonia).

For the primary and secondary objectives, advanced survival techniques (competing risks and multistate models) will be applied. Discharge and death will be considered as competing events for ICU pneumonia. Adapted Cox regression models will be applied for each event separately as well as for the sub-distribution of ICU pneumonia. The clustering of the data (readmission, patients within ICU, country) will be acknowledged using shared frailty methodology, stratification or robust variance. The time-dependency of cumulative hazards and incidences will be graphically displayed, by risk factors of interest. Hazard ratios with 95% CI will be calculated univariately and selected for the multivariate model using an established Akaike’s information criterion for model selection. A risk prediction model will be developed to quantify the risk for acquiring S. aureus or P. aeruginosa ICU pneumonia during ICU stay by using a composite score of independent risk factors.

Quality assurance

Data will be entered in a web-based electronic data capture system that was designed for ASPIRE-ICU. The study site will enter data in the electronic data capture system from the subject’s source documents (i.e. medical chart). Information linking the subject ID to the subject’s medical file (only applicable for study cohort subjects) will be kept in a secure place at the participating study site.

Monitoring will include 100% source data verification for the first three enrolled study cohort subjects at each site, and then 10% of the remaining enrolled study cohort subjects.

Discussion

This manuscript describes the objectives and design of ASPIRE-ICU, an observational cohort study addressing risk factors for S. aureus and P. aeruginosa ICU pneumonia. Certain choices have been made in the design that warrant mention and further discussion.

Definition of pathogen-specific pneumonia

The definition of S. aureus or P. aeruginosa ICU pneumonia is based on pre-defined pneumonia criteria in combination with the presence of the bacterium in an appropriate sample around the time of diagnosis, which are aligned with endpoints being used for two randomized controlled trials for prevention of S. aureus and P. aeruginosa pneumonia [8]. Thus, in case of cultures that yield multiple possible pathogens, it may be that the diagnosis of S. aureus or P. aeruginosa pneumonia is made incorrectly. The distinction between colonization and infection is sometimes difficult to assess. There is however no ‘reference standard’ to reliably assess the causative pathogen [3]. We have contemplated quantitative cultures in all pneumonia patients, but it was not feasible to implement this at each site. Quantitative measurements will however be applied on study samples received by the central laboratory, and thus will provide additional retrospective information. Furthermore, other outcomes, such as mortality will provide objective outcome information in addition to a diagnosis of pneumonia.

Enrichment strategy

In this study, 50% of the study cohort population is S. aureus colonized at ICU admission to ‘enrich’ the study population with S. aureus carriers (in nose or lower respiratory tract), while this naturally occurs in approximately 20–25% of the ICU population [10]. This was chosen as S. aureus carriage is being studied as one of the main known risk factors for subsequent S. aureus disease, thus without enrichment, the population needed for equal precision would be much larger [9, 11, 12]. However, the limitation of this choice is that one can argue that a population as such is not representative of the general ICU population, thus incidence estimation as well as assessing risk factors for P. aeruginosa ICU pneumonia may be suboptimal. We acknowledge this, and for this reason the surveillance population was included. Their data will allow distribution of baseline factors with the study cohort in an effort to assess the ubiquity of results across both groups. Furthermore, it can serve to identify potential bias between participants and non-participants. Considering that P. aeruginosa colonization at ICU admission is relatively rare and that colonization often occurs after ICU admission, no recruitment selection for P. aeruginosa colonized subjects will take place [13].

Routine surveillance

This study utilizes routine S. aureus screening conducted at each participating site as the basis for eligibility assessment. For consistency of screening results across sites, all swabs will be plated under protocol on the same chromogenic agar plates (Colorex agar, bioTRADING Benelux) provided by the ASPIRE-ICU study team. In the original protocol, a nose swab and ETA sample (sputum sample if non-intubated) are collected at screening. However, soon after study start, the protocol was amended to include a throat sample as a LRT sample, in case ETA and sputum were both not feasible.

Future perspectives

In this era of increasing antimicrobial resistance, the research field is steadily exploring other therapies, for example prophylactic therapies such as antibody-based preventive measures. A potential advantage of monoclonal antibodies (mAbs) is that they will not encourage bacterial resistance to the same extent as antibiotics, and may even augment antibiotic effectiveness [14]. This study was designed in part to provide crucial information on the incidence, patient-related and contextual factors of ICU pneumonia caused by S. aureus and P. aeruginosa, but also inform the design of future phase III trials, that will investigate mAbs effectiveness against S. aureus and P. aeruginosa. Two large COMBACTE phase II trials, SAATELLITE (A Human Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin in Mechanically Ventilated Adult Subjects) and EVADE (Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas aeruginosa in Mechanically Ventilated Subjects) have already started [8]. SAATELLITE investigates the effect of MEDI4893, a mAb targeting S. aureus alpha toxin and EVADE studies MEDI3902, which is another mAb that simultaneously targets PcrV and Psl on the surface of the P. aeruginosa bacterium, in subjects at risk for ICU pneumonia [5, 6, 8]. These targeted therapies, if proven effective, may be used in the future for patients at highest risk. This study will help to identify the subset of patients that will likely benefit most.

Conclusion

This epidemiological cohort study on S. aureus and P. aeruginosa ICU pneumonia aims to add significant information to the literature on predictors for this event. This will help refine the design of Phase III trials and may benefit patients at risk for nosocomial infections, by providing protective measures.

Abbreviations

ASPIRE-ICU: 

Advanced understanding of Staphylococcus aureus and Pseudomonas aeruginosa Infections in EuRopE

CI: 

Confidence interval

COMBACTE: 

COMBatting AntibiotiC resisTance in Europe

ETA: 

Endotracheal aspirate

ICU: 

Intensive Care Unit

LOS: 

Length of stay

LRT: 

Lower respiratory tract

mAb: 

Lower respiratory tract

P. aeruginosa : 

Pseudomonas aeruginosa

S. aureus : 

Staphylococcus aureus

Declarations

Acknowledgments

We would like to thank the following people for their contributions while writing this study protocol: Stephan Harbarth, Mark Eickhoff, Bruno François, Frank Coenjaerts, Uwe Völker, Barbara Bröker, Andreas Peschel, Willem Van Wamel, Gerard Lina, Jos Van Strijp, Samir Kumar-Singh, Antonio Oliver, Christian Van Delden, Thilo Kohler, Tom van der Poll, Craig Maclean.

Funding

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115523 and 115737 resources which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007–2013) and EFPIA companies in kind contribution.

Availability of data and materials

The datasets generated and analyzed during the current study are not publicly available due to confidentiality reasons but are available from the corresponding author upon scientific review and approval of the request by the Study’s Scientific Committee. A summary of the results will be published on clinicaltrials.gov.

Authors’ contributions

FPP authored the original study protocol and this manuscript. FPP, DPRT, FS, CL, RK, DP, LT, HG, SMK, MJMB and JAJW together created the study design. MW and SW, with help of all other authors designed the Statistical Analysis Plan. All authors read and approved the study protocol and the final manuscript.

Ethics approval and consent to participate

This study will be conducted according to the principles of the Declaration of Helsinki, in accordance with the Medical Research Involving Human Subjects Act (WMO) and local guidelines in the participating countries. [15] Central IEC’s in each participating country gave a favorable opinion to the study protocol, including informed consent procedures.

Consent for publication

Not applicable.

Competing interests

FS is an employee of AstraZeneca. RK is an employee of MedImmune. The other authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, HP Stratenum 6.131, PO Box 85500, 3508 GA Utrecht, The Netherlands
(2)
Institute for Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany
(3)
MedImmune, Gaithersburg, MD, USA
(4)
Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium
(5)
AstraZeneca Pharmaceuticals LP, Gaithersburg, MD, USA
(6)
Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands
(7)
Amphia Hospital, Breda, The Netherlands

References

  1. Chastre J, Fagon J-Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med American Thoracic SocietyNew York, NY. 2002;165:867–903. doi:10.1164/ajrccm.165.7.2105078.View ArticleGoogle Scholar
  2. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. EPIC international advisory committee. JAMA. 1995;274:639–44. Available: http://www.ncbi.nlm.nih.gov/pubmed/7637145.View ArticlePubMedGoogle Scholar
  3. Douglas IS. New diagnostic methods for pneumonia in the ICU. Curr Opin Infect Dis. 2016;29:197–204. doi:10.1097/QCO.0000000000000249.View ArticlePubMedGoogle Scholar
  4. François B, Jafri HS, Bonten M. Alternatives to antibiotics. Intensive Care Med. 2016;42:2034–6. doi:10.1007/s00134-016-4339-y.View ArticlePubMedGoogle Scholar
  5. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus Aureus-induced pneumonia. Antimicrob agents Chemother. Am Soc Microbiol (ASM). 2014;58:1108–17. doi:10.1128/AAC.02190-13.Google Scholar
  6. DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P, Minter R, et al. Identification of broadly protective human antibodies to Pseudomonas Aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med. 2012;209:1273–87. doi:10.1084/jem.20120033.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Kostyanev T, Bonten MJM, O’Brien S, Steel H, Ross S, François B, et al. The innovative medicines Initiative’s new drugs for bad bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. J Antimicrob Chemother Oxford University Press. 2016;71:290–5. doi:10.1093/jac/dkv339.View ArticleGoogle Scholar
  8. François B, Chastre J, Eggiman P, Laterre P-F, Torres A, Sanchez M, et al. The SAATELLITE and EVADE clinical studies within the COMBACTE consortium: a public–private collaborative effort in designing and performing clinical trials for novel antibacterial drugs to prevent Nosocomial pneumonia: table 1. Clin Infect Dis. 2016;63:S46–51. doi:10.1093/cid/ciw245.View ArticlePubMedGoogle Scholar
  9. Paling FP, Wolkewitz M, LGM B, PMC KK, DSY O, Depuydt P, et al. Staphylococcus Aureus colonization at ICU admission as a risk factor for developing S. Aureus ICU pneumonia. Clin Microbiol Infect. 2017;23:49.e9-49.e14. doi:10.1016/j.cmi.2016.09.022.View ArticlePubMedGoogle Scholar
  10. Wertheim HFL, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, et al. The role of nasal carriage in Staphylococcus Aureus infections. Lancet Infect Dis. 2005;5:751–62. doi:10.1016/S1473-3099(05)70295-4.View ArticlePubMedGoogle Scholar
  11. Ziakas PD, Anagnostou T, Mylonakis E. The prevalence and significance of methicillin-resistant Staphylococcus Aureus colonization at admission in the general ICU setting: a meta-analysis of published studies. Crit Care Med. 2014;42:433–44. doi:10.1097/CCM.0b013e3182a66bb8.View ArticlePubMedGoogle Scholar
  12. Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR. Methicillin-resistant Staphylococcus Aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis. 2004;39:776–82. doi:10.1086/422997.View ArticlePubMedGoogle Scholar
  13. Kollef MH, Chastre J, Fagon J-Y, François B, Niederman MS, Rello J, et al. Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas Aeruginosa. Crit Care Med. 2014;42:2178–87. doi:10.1097/CCM.0000000000000510.View ArticlePubMedGoogle Scholar
  14. Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine. 2009;27(Suppl 6):G38–46. doi:10.1016/j.vaccine.2009.09.105.View ArticlePubMedPubMed CentralGoogle Scholar
  15. World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4. doi:10.1001/jama.2013.281053.View ArticleGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement

BMC Infectious Diseases

ISSN: 1471-2334

Contact us